Jacobs Levy Equity Management, Inc Sarepta Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 753,845 shares of SRPT stock, worth $82.3 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
753,845
Previous 690,408
9.19%
Holding current value
$82.3 Million
Previous $109 Million
13.69%
% of portfolio
0.38%
Previous 0.47%
Shares
17 transactions
Others Institutions Holding SRPT
# of Institutions
528Shares Held
84MCall Options Held
1.99MPut Options Held
1.36M-
Black Rock Inc. New York, NY10.3MShares$1.13 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.97MShares$978 Million0.02% of portfolio
-
Capital International Investors Los Angeles, CA6.26MShares$683 Million0.16% of portfolio
-
Janus Henderson Group PLC London, X04.36MShares$476 Million0.29% of portfolio
-
State Street Corp Boston, MA4.27MShares$466 Million0.02% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $9.55B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...